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Background
Safety of antidepressants in children and adolescents is
being questioned and their efficacy in juvenile depression
remains uncertain. Our aim was to assess antidepressant
efficacy in juvenile depression.
Materials and methods
Systematic review and meta-analysis of randomised con-
trolled trials (RCTs) comparing responses to antidepres-
sants, overall and by type, vs. placebo in depressed
juveniles.
Results
Thirty drug-placebo contrasts in RCTs lasting 8 weeks
(median), involved 2979 subjects (456 person-years) of
average age 13.5 years. Meta-analysis yielded a modest
pooled drug/placebo response rate ratio (RR=1.22,
95%CI: 1.15-1.31), with little separation among antide-
pressant-types. Findings were similar for rate differences
(RD) and Corresponding number-needed-to-treat (over-
all NNT: 10; TCAs [13] > SRIs [9] > Others [8]). NNTs
decreased with increasing age: children (22) > mixed-ages
(11) > adolescents (8).
Conclusions
Antidepressants of all types showed limited efficacy in
juvenile depression, but fluoxetine might be more effec-
tive, especially in adolescents. Studies in children, severely
depressed, hospitalised or suicidal juveniles are needed,
and effective, safe, and readily accessible treatments for
juvenile depression are urgently required.
Acknowledgements
The authors thank the Royal College of Psychiatrists of England for award-
ing an Eli Lilly Travelling Fellowship to EMT, the Ph.D. program in Psychiatry 
of the University of Pisa, the Harvard School of Public Health doctoral pro-
gram in Epidemiology, and the IDEA Foundation, Milan for supporting FS, 
and the Bruce J. Anderson Foundation and the McLean Private Donors Psy-
chopharmacology Research Fund for research grants to RJB.
from International Society on Brain and Behaviour: 3rd International Congress on Brain and Behaviour
Thessaloniki, Greece. 28 November – 2 December 2007
Published: 17 April 2008
Annals of General Psychiatry 2008, 7(Suppl 1):S350 doi:10.1186/1744-859X-7-S1-S350
<supplement> <title> <p>International Society on Brain and Behaviour: 3rd International Congress on Brain and Behaviour</p> </title> <note>Meeting abstracts - A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1744-859X-7-S1-full.pdf">here</a>.</note> </supplement>
This abstract is available from: http://www.annals-general-psychiatry.com/content/7/S1/S350
© 2008 Tsapakis et al.; licensee BioMed Central Ltd. 
